Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake

Muscle and Nerve

Volumn 30, Issue 6, 2004, Pages 803-807

  Vasconcelos, Olavo M ^a   Campbell, William W ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Dermatomyositis; HMG CoA reductase inhibitors; Rhabdomyolysis; Simvastatin; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; PRAVASTATIN; PREDNISONE; SIMVASTATIN; STEROID;

AGED; ARTICLE; CAREGIVER; CASE REPORT; CORONARY ARTERY DISEASE; DERMATOMYOSITIS; DERMATOMYOSITIS LIKE SYNDROME; FATIGUE; GASTROESOPHAGEAL REFLUX; GOUT; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MALAISE; MALE; MUSCLE DISEASE; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; PANCYTOPENIA; PRIORITY JOURNAL; RASH; REMISSION;

AGED; DERMATOMYOSITIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SYNDROME;

EID: 10044231566     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20127     Document Type: Article

References (41)

1. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin. Arch Intern Med 1991;151:1667-1668.
2. Berland Y, Vacher CH, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use. Nephron 1991;57:365-366.
3. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993;94:109-110.
4. Cronin ME, Plotz PH. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1990;16:655-665.
5. Curran JJ, Jamieson TW. Dermatomyositis-like syndrome associated with phenylbutazone therapy. J. Rheumatol 1987;14:397-398.
6. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-48.
7. England JD, Walsh JC, Stewart P, Boyd I, Roban A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors - simvastatin and pravastatin. Aust N Z J Med 1995;25:374-375.
8. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-1385.
9. Feldmann R, Mainetti C, Saurat JH. Skin lesions due to treatment with simvastatin (Zocor). Dermatology 1993;186:272.
10. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-569.
11. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-229.
12. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1601.
13. Hawkins RA, Eckhoff PJ Jr, MacCarter DK, Harmon CE. Cimetidine and polymyositis. N Engl J Med 1983;309:187-188.
14. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995;25:745-746.
15. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997;277:296-297.
16. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-341.
17. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1993;32:647-648.
18. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993;186:248-252.
19. Landesman KA, Stozek M, Freeman NJ. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med 1999;63:455-457.
20. Leff RL, Love LA, Miller FW, Greenberg SJ, Klein EA, Dalakas MC, Plotz PH. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992;339:1192-1195.
21. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991;41:1159-1160.
22. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myosius specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-374.
23. Martinez-Garcia FA, Martin-Fernandez J, Molto JM, Villaverde R, Morales A, Fernandez-Barreiro A. Myopathy caused by inhibitors of hydroxymethylglutaryl- coezyme A reductase. Rev Neurol (Paris) 1997;25:869-871.
24. McDonagh J, Winocour P, Walker DJ. Musculoskeletal manifestations during simvastatin therapy. Br J Rheumatol 1993;32:647-648.
25. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-268.
26. Pachman LM, Litt DL, Rowley AH, Hayford JR, Caliendo J, Heller S, Ticho BS, Chirtensen M, Patterson B, Ytterberg SR, Pallansch M. Lack of detection of enteroviral RNA or bacterial DNA in MRI directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum 1995;38:1513-1518.
27. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JDF. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
28. Pierno S, De Luca A, Tricarico D, Roselli A, Natuzzi F, Ferrannini E, Laico M, Camerico DC. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 1995;275:1490-1496.
29. Rodriguez-Garcia JL, Serrano CM. Lovastatin-associated dermatomyositis. Postgrad Med J 1996;72:694.
30. Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K, Tanigawara Y, Okumura K. Simvastatin and lovastatin, but not pravastatin, interact with MDRI. J Pharm Pharmacol 2002;54:419-423.
31. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;327:649-650.
32. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997;90:546-547.
33. Targoff IN. Autoantibodies. In: Wortmann RL, editor. Diseases of skeletal muscles. Philadelphia: Lippincott, Williams & Wilkins; 2000. p 267-296.
34. Targoff IN, Miller FW, Medsger TAJr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-539.
35. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996;240:403-404.
36. van Vliet AK, Negre-Aminou P, van Thiel GCF, Bolhuis PA, Cohen LH. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiprolipherative effect in cultured myoblasts from human striated muscles. Biochem Pharmacol 1996;52:1387-1392.
37. Veerkamp JH, Smit JW, Benders AA, Oosterhof A. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta 1996;1315:217-222.
38. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet 1989;1097-1098.
39. Wartmann RL. Inflammatory diseases of muscle and other myopathies. In: Ruddy S, Harris ED, Sledge CB, editors. Kelley's textbook of rheumatology, 4th ed. Philadelphia: WB Saunders; 1993. p 1159-1188.
40. Wicher-Muniak E, Zmudka K, Dabros W, Dudek D, Stachura J. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects. Pol J Pathol 1997;48:69-74.
41. Wojnarowska F. Dermatomyositis induced by penicillamine. J R Soc Med 1980;73:884-886.